DUSP22 (dual specificity phosphatase 22)

2003-06-01  

Identity

HGNC
LOCATION
6p25.3
LOCUSID
ALIAS
JKAP,JSP-1,JSP1,LMW-DSP2,LMWDSP2,MKP-x,MKPX,VHX
FUSION GENES

Other Information

Locus ID:

NCBI: 56940
MIM: 616778
HGNC: 16077
Ensembl: ENSG00000112679

Variants:

dbSNP: 56940
ClinVar: 56940
TCGA: ENSG00000112679
COSMIC: DUSP22

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000112679ENST00000344450Q9NRW4
ENSG00000112679ENST00000344450A0A384NLC8
ENSG00000112679ENST00000419235Q9NRW4
ENSG00000112679ENST00000603296S4R3A4
ENSG00000112679ENST00000603453S4R3M1
ENSG00000112679ENST00000603726S4R459
ENSG00000112679ENST00000603795S4R459
ENSG00000112679ENST00000603881S4R3K1
ENSG00000112679ENST00000604971S4R3M1
ENSG00000112679ENST00000605035S4R378
ENSG00000112679ENST00000605315S4R3M1
ENSG00000112679ENST00000605863S4R378

Expression (GTEx)

0
10
20
30
40
50
60
70
80
90

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
379379152024DUSP22 suppresses tumor progression by directly dephosphorylating AKT in non-small cell lung cancer.0
382252652024The phosphatase DUSP22 inhibits UBR2-mediated K63-ubiquitination and activation of Lck downstream of TCR signalling.1
384958102024DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways.0
388514182024Exosomal miR-1228-5p down-regulates DUSP22 to promotes cell proliferation and migration in small cell lung cancer.0
379379152024DUSP22 suppresses tumor progression by directly dephosphorylating AKT in non-small cell lung cancer.0
382252652024The phosphatase DUSP22 inhibits UBR2-mediated K63-ubiquitination and activation of Lck downstream of TCR signalling.1
384958102024DUSP22 Ameliorates Endothelial-to-Mesenchymal Transition in HUVECs through Smad2/3 and MAPK Signaling Pathways.0
388514182024Exosomal miR-1228-5p down-regulates DUSP22 to promotes cell proliferation and migration in small cell lung cancer.0
364531042023DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.6
364531052023ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.6
364531062023DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.5
367653052023Dual-specificity phosphatases 22-deficient T cells contribute to the pathogenesis of ankylosing spondylitis.3
381799962023Serum JKAP reflects Th2 and Th17 cell levels, and diabetic nephropathy risk and severity in diabetes mellitus patients.0
364531042023DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.6
364531052023ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.6

Citation

Dessen P

DUSP22 (dual specificity phosphatase 22)

Atlas Genet Cytogenet Oncol Haematol. 2003-06-01

Online version: http://atlasgeneticsoncology.org/gene/40373/js/favicon/apple-touch-icon.png